PROX1 and gastric cancer: In addition, by including data from a previous study of cytoplasmic PROX1 expression in gastric cancer tissue samples from the same patient cohort, we discovered that 5‐year disease‐specific survival among patients with positive nuclear and high cytoplasmic expressions reached nearly 70%.18